Cagrilintide

Human clinical Weight Loss & Metabolism 2 sources

Cagrilintide is a long-acting amylin analog that mimics the natural hormone amylin to regulate blood sugar and promote satiety. Research shows it significantly reduces body weight and improves glycemic control, especially when combined with GLP-1 receptor agonists like semaglutide.

01Dosing reference

Amount

0.3 to 4.5 mg

Frequency

Once weekly

Cycle

Continuous use under clinical trial protocols (dose escalation over several weeks)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Amylin receptor agonism

Binds to and activates amylin receptors located primarily in the hindbrain.

Satiety signaling and gastric emptying

Delays gastric emptying and increases feelings of fullness by modulating appetite-regulating pathways.

Weight loss and glycemic control

Leads to reduced caloric intake and improved postprandial glucose levels, contributing to significant weight loss.

03Human evidence

Significant weight loss in Phase 2 trials

In a Phase 2 trial, cagrilintide alone or in combination with semaglutide led to substantial weight reduction in individuals with overweight or obesity.

Improved glycemic control in Type 2 Diabetes

Studies show improvements in HbA1c levels when used in patients with type 2 diabetes, with a safety profile similar to other incretin-based therapies.

04Preclinical evidence

Synergistic effects with GLP-1 agonists

Animal models demonstrated that combining amylin analogs with GLP-1 receptor agonists produces greater weight loss than either agent alone.

Reduction in food intake

Rodent studies showed a dose-dependent decrease in food consumption following cagrilintide administration.

05What is known vs. unknown

Reasonably established

Acts as a long-acting amylin analog.
Promotes weight loss by increasing satiety and delaying gastric emptying.
Currently in late-stage clinical trials, often studied in combination with semaglutide (CagriSema).
Administered via subcutaneous injection, typically once weekly.

Unknowns & limits

Long-term cardiovascular outcomes and safety profile are still being evaluated in ongoing Phase 3 trials.
The exact long-term tolerability compared to standalone GLP-1 therapies remains to be fully established.

06Safety & regulatory context

Regulatory statusCagrilintide is an investigational drug and is not yet FDA-approved for general use. In clinical trials, the most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea, similar to GLP-1 receptor agonists. It is being studied primarily as a once-weekly subcutaneous injection. Regulatory approval will depend on the outcomes of ongoing Phase 3 clinical trials.

07Compared with Semaglutide

Cagrilintide vs. Semaglutide

Key difference

Cagrilintide is an amylin analog targeting amylin receptors, whereas semaglutide is a GLP-1 receptor agonist targeting GLP-1 receptors.

When researchers discuss each

Researchers discuss semaglutide for its established role in incretin-based weight loss and diabetes management, while cagrilintide is discussed as a complementary mechanism that can be combined with GLP-1s for synergistic effects.

08Glossary

Amylin

A peptide hormone co-secreted with insulin from the pancreas that plays a role in glycemic regulation by slowing gastric emptying and promoting satiety.

Agonist

A substance that binds to a receptor and activates it to produce a biological response.

Gastric Emptying

The process by which food leaves the stomach and enters the small intestine.

09Knowledge check

Q1What is the primary mechanism of action of cagrilintide?

Q2Which drug is cagrilintide most frequently combined with in clinical trials for synergistic weight loss?

Q3Which limitation about cagrilintide is explicitly noted in the dossier?

Q4When researchers discuss cagrilintide alongside semaglutide, which statement best reflects the comparison context described in the dossier?

Q5Which of the following statements about cagrilintide's regulatory and safety status is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.